Searchable abstracts of presentations at key conferences in endocrinology

ea0040l10 | ALTered telomeres in pancreatic neuroendocrine tumors | ESEBEC2016

ALTered telomeres in pancreatic neuroendocrine tumors

Perren Aurel , Marinoni Ilaria

Neuroendocrine tumors do not share many classical pathways of tumorigenesis with their non-endocrine counterparts. In recent years, the molecular understanding of of pancreatic neuroendocrine tumors (PanNET) tumorigenesis has made major advances. A whole exome NGS analysis described frequent mutations of two new genes DAXX and ATRX. 40% of unselected panNET show mutations in one of these genes. Mutations in these genes are associated with loss of the respecti...

ea0041ep591 | Endocrine tumours and neoplasia | ECE2016

Mtor inhibitors responsiveness associates with Akt/Mtor pathway activation in pancreatic neuroendocrine tumors

Falletta Simona , Partelli Stefano , Rubini Corrado , Nann Dominik , Doria Andrea , Marinoni Ilaria , Polenta Vanessa , Di Paquale Carmelina , Uberti Ettore Degli , Perren Aurel , Falconi Massimo , Zatelli Maria Chiara

Introduction: Medical therapy of Pancreatic neuroendocrine tumors (P-NETs) may take advantage from mammalian target of rapamycin (mTOR) inhibitors. However, so far, the extent of therapeutic response cannot be predicted.Aim: To investigate the possible predictors of sensitivity to mTOR inhibitors in P-NETs.Materials and methods: P-NET primary cultures were treated with IGF1 and/or Everolimus. Cell viability and caspase activity wer...